Comparing Gemcitabine Plus Nab-Paclitaxel Switch Maintenance to Continuing Modified FOLFIRINOX in Advanced Pancreatic Cancer PANThEON Phase III Trial
Led by Gruppo Oncologico del Nord-Ovest · Updated on 2026-09-09
340
Participants Needed
28
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting the PANThEON trial, a randomized, open-label, multicenter phase III study, to compare two chemotherapy approaches in patients with advanced pancreatic adenocarcinoma that cannot be surgically removed or has spread. The study aims to evaluate overall survival by comparing continuing modified FOLFIRINOX versus switching to gemcitabine plus nab-paclitaxel after initial induction chemotherapy. Eligible patients have stable or responding disease after about 3 months of initial mFOLFIRINOX treatment.
During the study, all participants first receive induction chemotherapy with mFOLFIRINOX for up to 14 weeks, consisting of about six cycles every two weeks. Patients who show no disease progression are then randomly assigned to either continue mFOLFIRINOX Arm A or switch to gemcitabine plus nab-paclitaxel Arm B. Arm A treatments include oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil given every two weeks until progression or unacceptable side effects. Arm B treatments involve gemcitabine and nab-paclitaxel administered on days 1, 8, and 15 of each 28-day cycle until progression or toxicity.
Participants will have tumor imaging before and after induction chemotherapy to assess response. Throughout the trial, researchers will monitor overall survival up to 48 months, along with other outcomes like progression-free survival, treatment failure time, response rates, quality of life, and treatment toxicity. Safety and disease status will be regularly assessed, and participants may continue treatment or withdraw as needed. The trial is expected to last until 2030, with ongoing follow-up for health status and outcomes.
CONDITIONS
Brief Title
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
Research Team
M
Monica Niger, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Serious medical conditions that impair ability to participate
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Induction Chemotherapy
Duration - Up to 14 weeks
Participants receive mFOLFIRINOX chemotherapy every two weeks for up to 14 weeks (about 6 cycles) to control cancer before randomization.
Bi-weekly visits for treatment and assessments
Randomized Treatment
Duration - Variable, until disease progression or other stopping criteria
Participants are randomly assigned to either continue mFOLFIRINOX or switch to gemcitabine plus nab-paclitaxel. Treatment continues until disease progression, unacceptable toxicity, withdrawal, or death.
Regular visits as per treatment schedule
Follow-up
Duration - Up to 48 months
Participants are monitored for survival, disease progression, side effects, and quality of life for up to 48 months after randomization.
Periodic visits for assessments and monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluation of INV-8989 Safety, Drug Behavior, and Early Anti-Cancer Effects in Adults with KRAS G12D Mutated Advanced Solid Tumors
Phase 1a1b Study of CT-95 for Treating Advanced Cancers with Mesothelin Expression
Comparing Gemcitabine Plus Nab-Paclitaxel Switch Maintenance to Continuing Modified FOLFIRINOX in Advanced Pancreatic Cancer PANThEON Phase III Trial
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A phase III randomized clinical trial of Gemcitabine and Nab-Paclitaxel as switch maintenance versus continuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: The PANThEON Study.